Scientific deep-dive
Beyond BMI: Who Actually Needs Treatment
Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups, so treating by risk costs nothing in weight lost.
Every insurer, every prescriber and every telehealth intake in this market decides who gets treatment using BMI. A study in Nature Medicine built a model from thousands of candidate features and showed what that threshold hides: among people all above a BMI of 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%.[1] That is a fifty-seven-fold difference, and the number being used cannot see it. How obesity is defined today, BMI cut-offs included, is set out on our obesity condition page.
What the model does
Starting from thousands of tested features, the researchers identified the twenty most informative for predicting the future onset of eighteen obesity complications, and combined them into a single score. It stratified people into risk groups that behaved very differently over ten years, and it generalized to independent populations of both European and non-European ancestry.[1]
| Risk group | Cardiovascular mortality over 10 years |
|---|---|
| Highest | 5.7% |
| 1.8% | |
| Middle | 0.9% |
| 0.4% | |
| Lowest | 0.1% |
Everyone in that table meets the same BMI criterion. One group faces more than fifty times the risk of another, and the criterion cannot tell them apart.
The finding that should change policy
The researchers then applied the score to participants in the SURMOUNT-1 tirzepatide trial and asked whether baseline risk predicted how well the drug worked.
Weight loss was similar across baseline risk groups.
That sentence from the paper is the one that matters.[1] If the highest-risk people lose about as much weight as the lowest-risk people, then treating by risk rather than by BMI costs nothing in weight lost and should gain a great deal in benefit. The same drug, given to someone facing 5.7% cardiovascular mortality instead of someone facing 0.1%, should do far more good for the same money, although the paper did not test that directly.
Predicted risks also decreased following treatment with tirzepatide. That is a modeled decrease, not a count of observed events.
What the study does not establish
- It is a prediction model, not a treatment trial. It identifies who is at risk. It does not demonstrate that allocating treatment by this score improves outcomes, which would require its own trial.
- The risk reduction is modeled. “Predicted risks decreased” means the score fell, not that events were counted.
- Twenty features is still a lot to collect. A score that outperforms BMI only when you have twenty inputs is harder to use than a number from a scale and a tape measure.
- Three of the authors work for Eli Lilly, which makes tirzepatide. One of them ran the SURMOUNT-1 analysis. The paper states that Lilly did not fund the study.[1]
- It does not tell an individual what to do. A risk group is a population, and our note on averages applies here as everywhere.
Why BMI persisted anyway
BMI has real strengths. It is free, instant, requires no laboratory, and is calculable by anyone with a scale. That universality is exactly why it became the gate.
Its weaknesses are just as well known. It does not distinguish fat from muscle, distributes differently across populations, and says nothing about where fat sits or what it is doing metabolically. What is new here is a demonstration of how much risk information a BMI threshold discards, and evidence that acting on that information would cost nothing in treatment response.
Frequently Asked Questions
References
- 1.Demircan K, Carrasco-Zanini J, Williamson A, et al. Data-driven prioritization of high-risk individuals for weight loss interventions Nature Medicine. 2026. PMID: 42062622.
Compare the sellers
Related research
The Cost-Effectiveness Case, and What Is Inside It
A model projects tirzepatide saving $41,688 per patient and adding half a quality-adjusted life year. Nobody measured that. It was computed, and the adherence assumption is doing most of the work.
5 min read
What These Drugs Do Outside a Trial
Across 44,025 people: semaglutide produced 5.4% weight loss at one year, tirzepatide 9.1%. The pivotal trials reported 14.9% and 20.9%. Continuous therapy recovers about a fifth of the gap.
6 min read
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.
6 min read
Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison
A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.
6 min read
Who Responds in the Real World
Tirzepatide nearly doubled the share reaching 15% weight loss in a year. The same study found outcomes differing by race, where 64 randomized trials found none. The disagreement is the finding.
6 min read
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
5 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $179/mo, prepaid
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $129/mo
Get started →Embody
From $129/mo
Get started →